LZCap AU (3'Acm), High Affinity (100mM)

Mfr.No.	10685ES80, 10685ES60
Description	LZCap AU (3'Acm) is a cap1 analog. The product is used for transcription with the initial sequence of 5'AU3', and the natural cap1 structure is produced by Cap1 transcription capping. Compared with Cap0 produced by traditional capping method, the cap1 structure produced by CapAU (3'Acm) enables the SaRNA to have higher activity and translation efficiency in vivo.
Molecular Formula	C₃₄H₄₇N₁₃O₂₅P₄ (Free acid)
Precautions	For your safety and health, please wear personal protective equipment (PPE), such as laboratory coats and disposable gloves, when operating with this product. For research use only.
Concentration	100± 3 mM
Molecular Weight	1161.71(Free acid)

Purity	HPLC ≥95%
Storage	This product could be stored at -25~-15 ℃ for two years.

Protocol	1． Thaw components required for the experiment on ice. 2． Refer to the following reaction system to configure the transcription system at room temperature. Modified N1-Me-pUTP can be used in place of wild-type UTP. The modified N1-Me-pUTP reduces the immunogenicity of mRNA. Henovcom can also provide modified nucleotide N1-Me-pUTP. Notes: 1) LZCap®AU(3'Acm) is suitable for T7 promoter transcription vector with 5 ‘AU 3’initiated sequences, which needs to be considered when constructing the vector. 2) The reagents, consumables and containers used in the experiment are free of RNase contamination. 3) It is recommended to use a linearized DNA template for transcription. 4) When modified nucleotides were used in place of wild-type nucleotides, the final concentration of the reaction was unchanged. 5) If the PCR product is used as the transcription initiation DNA template, the amount of DNA template can be reduced by half. 3． Mix the prepared reaction solution, centrifuge briefly, and incubate at 37°C for 2-3 hours. If the transcript length is less than 100nt, increase the reaction time to 4-8 h.

Modified N1-Me-pUTP can be used in place of wild-type UTP. The modified N1-Me-pUTP reduces the immunogenicity of mRNA. Henovcom can also provide modified nucleotide N1-Me-pUTP (Cat. No.: HN1002 ).

Have you used this product?

Rate it now..!!

Combination SKU	Supplier No.	Size	Your price	Quantity
BHN20800030-100uL	10685ES60	100 uL	$1000		Add to Cart
BHN20800030-1mL	10685ES80	1 mL	$8000		Add to Cart

1. How do you design the LZCap?

Enzymes have a relatively "specific" recognition of substrates. Therefore, when designing a new cap structure, on one hand, we need novel structural modifications for patent purposes, but on the other hand, we strive to maintain similarity with natural/known structures as much as possible. The natural structure has a ribose 3' OH, which can be modified (e.g., methylation). Based on this consideration, we chose to add a carbon at the 3' position for patent novelty, followed by an NH to mimic the hydrogen bonding of OH, and then an acetyl group to reduce the basicity of NH and enhance its hydrogen bonding capability. The activity of LzCap is better than methylated natural cap, possibly due to increased hydrogen bonding. Compared to the methyl and methoxy groups, the acetyl amino group may also increase van der Waals interactions between the substrate (cap) and the initiating factor (enzyme).

2. Is the acetyl amino group stable?

The acetyl amino group is already sufficiently stable. It is much more stable than the 7-methylated position and the phosphodiester bond, which are the least stable parts of the cap.

Please contact us for more details about the LZCap licensing.

LZCap AU (3'Acm), High Affinity (100mM)

Contact us to order

Tel

Email

Contact us to order

Tel

Email

Reviews of LZCap AU (3'Acm), High Affinity (100mM)

Rate it now..!!